PhRMA supports Secretary Burwell’s goal of advancing affordable, high quality and patient centered health care, and today’s announcement represents an important step forward.
New medicines make important contributions to value in health care for patients, payers and policymakers, and we look forward to working with the secretary on this new initiative. As HHS works to evaluate and expand new models of health care payment and delivery, we believe it is essential they:
- Incorporate clear mechanisms for recognizing the value of new treatment advances, such as precision medicine and other new tests and treatments;
- Are grounded in strong quality measures and incentives, with emphasis on outcomes that matter to patients;
- Support shared decision making between providers and patients, which is informed by high quality evidence about the full range of available treatment options; and,
- Are transparent and enable manufacturers and other stakeholders to work collaboratively in support of high-quality, high-value health care.
Reflecting our commitment to advancing sound, patient-centered payment models, PhRMA recently released principles for payment and delivery system reform. We appreciate the important announcement made today by Secretary Burwell, and look forward to continue working with HHS and other stakeholders on these important issues.
John Castellani John J. Castellani is past President and Chief Executive Officer of the Pharmaceutical Research and Manufacturers of America (PhRMA). He is a passionate advocate for a strong, innovative and growing American biopharmaceutical research industry that plays a critical role in helping to improve the health of every American and patients the world-over. Mr. Castellani is also the former President and CEO of Business Roundtable, an association of chief executive officers of leading U.S. corporations with a combined workforce of nearly 12 million employees and $6 trillion in annual revenues.